- Home
- HIHO vs APLM Comparison
HIHO vs APLM Comparison
Compare HIHO & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIHO
- APLM
- Stock Information
- Founded
- HIHO 1990
- APLM 2016
- Country
- HIHO Hong Kong
- APLM United States
- Employees
- HIHO N/A
- APLM N/A
- Industry
- HIHO Industrial Machinery/Components
- APLM Blank Checks
- Sector
- HIHO Industrials
- APLM Finance
- Exchange
- HIHO Nasdaq
- APLM Nasdaq
- Market Cap
- HIHO N/A
- APLM 7.7M
- IPO Year
- HIHO 1996
- APLM N/A
- Fundamental
- Price
- HIHO $1.45
- APLM $6.20
- Analyst Decision
- HIHO
- APLM Strong Buy
- Analyst Count
- HIHO 0
- APLM 1
- Target Price
- HIHO N/A
- APLM $200.00
- AVG Volume (30 Days)
- HIHO 7.6K
- APLM 45.7K
- Earning Date
- HIHO 01-21-2025
- APLM 04-03-2025
- Dividend Yield
- HIHO 8.26%
- APLM N/A
- EPS Growth
- HIHO N/A
- APLM N/A
- EPS
- HIHO N/A
- APLM N/A
- Revenue
- HIHO $7,345,000.00
- APLM $1,687,000.00
- Revenue This Year
- HIHO N/A
- APLM N/A
- Revenue Next Year
- HIHO N/A
- APLM N/A
- P/E Ratio
- HIHO N/A
- APLM N/A
- Revenue Growth
- HIHO 11.36
- APLM 105.48
- 52 Week Low
- HIHO $1.39
- APLM $4.95
- 52 Week High
- HIHO $2.88
- APLM $60.00
- Technical
- Relative Strength Index (RSI)
- HIHO 21.92
- APLM 39.13
- Support Level
- HIHO $1.39
- APLM $6.20
- Resistance Level
- HIHO $1.88
- APLM $8.00
- Average True Range (ATR)
- HIHO 0.05
- APLM 1.27
- MACD
- HIHO -0.05
- APLM -0.34
- Stochastic Oscillator
- HIHO 7.69
- APLM 8.29
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.